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Abstract 
Objective: Nodding syndrome is a poorly understood epileptic encephalopathy characterized by a unique 
seizure type— head nodding— and associated with Onchocerca volvulus infection. We hypothesized that 
altered immune activation in the cerebrospinal fluid (CSF) and plasma of children with nodding syndrome 
may yield insights into the pathophysiology and progression of this seizure disorder.
Method: We conducted a case-control study of 154 children (8 years or older) with long-standing nodding 
syndrome and 154 healthy age-matched community controls in 3 districts of northern Uganda affected by 
nodding syndrome. Control CSF samples were obtained from Ugandan children in remission from 
haematological malignancy during routine follow-up. Markers of immune activation and inflammation 
(cytokines and chemokines) and complement activation (C5a) were measured in plasma and CSF using 
ELISA or Multiplex Luminex assays. O. volvulus infection was assessed by serology for anti-Ov16 IgG 
levels.
Results: The mean (SD) age of the population was 15.1 (SD 1.9) years and the mean duration of nodding 
syndrome from diagnosis to enrolment was 8.3 (SD 2.7) years. Majority with nodding syndrome had been 
exposed to O. volvulus 147/154 (95.4%) compared to community children 86/154 (55.8%), OR 17.04 (95% 
CI 7.33, 45.58), p<0.001. C5a was elevated in CSF of children with nodding syndrome compared to 
controls, (p<0.0001). The levels of other CSF markers tested were comparable between cases and controls 
after adjusting for multiple comparisons. Children with nodding syndrome had lower plasma levels of IL10, 
APRIL, CCL5 (RANTES), CCL2, CXCL13, MMP-9 compared to community controls (p<0.05 for all; 
multiple comparisons). Plasma CRP was elevated in children with nodding syndrome compared to 
community children and correlated with disease severity.
Significance: Nodding syndrome is associated with exposure to O. volvulus. Compared to controls, children 
with long-standing symptoms of nodding syndrome show evidence of complement activation in CSF and 
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Key points box (3-5) Please ensure each bullet point is no longer than 140 characters.
1. Long-standing nodding syndrome may be associated with complement activation in CSF.
2. The pathogenesis of chronic nodding syndrome may involve systemic and CSF immune alterations. 
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Introduction 
Nodding syndrome is a poorly understood severe neurological disorder characterized by a unique seizure 
manifesting as repeated head nods and complicated by other generalized seizures, motor, neuropsychiatric, 
and cognitive impairments1,2. In addition, undernutrition, delayed development of sexual characteristics and 
stunting is observed in a proportion of affected children. Nodding syndrome was initially reported in 
southern Tanzania, followed by South Sudan and later in northern Uganda3–5. More recently cases have been 
reported in central Africa6. Nodding syndrome occurs in previously normal children between the ages of 3-
18 years, it is chronic, shows progression in some, and frequently occurs in epidemics with clusters of cases 
observed in geographically distinct regions7,8. Clinical and electrophysiological studies suggest nodding 
syndrome may be an epileptic encephalopathy9. 
The aetiology of nodding syndrome remains unknown. It has been proposed that nodding syndrome may be 
linked to a nutritional, genetic, or an unknown infectious agent 10,11. However, several epidemiological 
studies have demonstrated a consistent relationship with O. volvulus infection leading to the hypothesis that 
O. volvulus may underlie the pathogenesis of nodding syndrome5,12–14. Confounding this hypothesis is the 
fact that O. volvulus is observed across Africa and in parts of Latin America15,16, whereas nodding syndrome 
is largely confined to east and central Africa 17. In addition, a proportion of healthy community controls 
typically have evidence of O. volvulus infection. Despite this, recent evidence suggests a link between 
seizure related disorders and O. volvulus leading to the study of a spectrum of syndromes - Onchocerca 
associated epilepsies (OAE).  The mechanism by which O. volvulus infection may led to nodding syndrome 
and/or the spectrum of disorder labelled as OAEs’ remains unclear. One school of thought has suggested 
that O. volvulus may be a secondary opportunistic infection unrelated to the aetiology of nodding 
syndrome18.  It has also been hypothesized that antibodies to O. volvulus or its symbiont Wolbachia may 
cross-react with neuronal proteins leading to neuro-inflammation and nodding syndrome 13. This hypothesis 
is supported by studies showing auto-antibodies against actin-binding protein leiomodin-119, and the 
voltage-gated potassium channel complex13 in the cerebrospinal fluid (CSF) of patients with nodding 
syndrome. A recent post-mortem study of brains from patients with nodding syndrome demonstrated 
evidence of past ventriculitis, meningitis and gliotic lesions suggesting nodding syndrome may be a post-
infectious encephalopathy20. 
We hypothesized that nodding syndrome is a neuro-inflammatory disorder associated with O. volvulus 
infection and systemic changes in immune and complement activation. To evaluate this, we measured 
markers of immune and complement activation in the cerebrospinal fluid and plasma of Ugandan children 
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Design 
This was an exploratory case-control study of neuro- and peripheral inflammation in children and 
adolescents with a long-standing diagnosis of nodding syndrome compared to frequency and age matched 
controls. Cerebrospinal fluid (CSF) and plasma concentrations of a selected panel of cytokines, chemokines, 
and complement factors, were assayed. 
Setting 
The study was conducted in the nodding syndrome affected districts of Kitgum, Pader and Lamwo in 
northern Uganda. (Figure 1). This region suffers high levels of poverty and is still recovering from a two-
decade old Lord’s Resistance Army war against the Government of Uganda. Subsistence farming is the 
major economic activity. The age-specific prevalence of nodding syndrome in the affected age group in 
these districts was approximately 6.8 (95% CI: 5.9-7.7) per 1,0004. Study participants were screened for 
eligibility at the nodding syndrome treatment centres within the respective districts13. Those enrolled were 
hospitalized in Kitgum General hospital (KGH) where all study procedures were conducted. KGH is the 
largest epilepsy and nodding syndrome treatment centre in the region.     
Ethical approval 
Ethical approval was obtained from Makerere University School of Medicine Research and Ethics 
Committee (SOMREC) and University of Oxford Tropical Medicine Research Ethics Committee 
(OXTREC).  Regulatory approvals were provided by Uganda National Council for Science and Technology 
(UNCST). Written informed consent was obtained from the primary caregiver of all participants enrolled in 
the study. In the event a caregiver was unable to read and write, consent was obtained using an independent 
witness and the caregiver provided a fingerprint.  Assent was obtained from all children, except from those 
that were severely cognitively impaired as judged by a trained psychologist. All consent forms are stored at 
the Centre of Tropical Neurosciences (CTN) for future reference.
Participants 
The study recruited 154 children and adolescents with nodding syndrome receiving standard symptomatic 
care at the dedicated treatment centres and 154 healthy community controls from neighbouring homes in the 
same communities. All nodding syndrome cases were 8 years or older and diagnosis was according to WHO 
criteria21: head nodding on two or more occasions, occurring in clusters at a frequency of 5-20/minute; 
observed by a trained health worker; onset between 3-18 years; plus any one of the following: a) triggered 
by food or cold weather; b) presence of other seizures or neurological abnormalities and cognitive decline; 
and c) clustering in space or time. The community controls were frequency matched based on prior defined 
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remission from a haematological malignancy as part of their routine follow-up at the Uganda Cancer 
Institute in Mulago hospital located in Kampala, Uganda. 
Clinical history and examination 
On enrolment, all participants had a detailed history taken to characterize the burden and type of seizures 
experienced in the previous month and a detailed physical exam including evaluations for neurologic, 
cognitive and psychiatric disorders. Finally, following standard aseptic collection methods, EDTA-
anticoagulated blood and CSF by lumbar puncture were obtained. Plasma was separated by centrifugation 
and all samples stored at -20 °C prior to transfer on dry ice to Kampala for long-term storage at -80 °C until 
testing. All samples were shipped on dry ice and sample integrity was confirmed on arrival. Exposure to O. 
volvulus was measured at the laboratory of parasitic research at the National Institute of Health, by 
evaluating levels of anti-OV-16 IgG in plasma as previously described 22. A sample was considered sero-
positive for O. volvulus when anti-OV-16 IgG signal-to-noise ratio was above a cut-off of 2. The cut-off was 
determined previously using receiver operator characteristic curves using ‘other helminth’ control samples22. 
The presence of active O. volvulus infection was determined by microscopy of saline solutions in which skin 
snips obtained from the iliac crest of all participants were incubated following standard microscopy 
protocols. 
As part of National Onchocerciasis control programs, all children in the region receive bi-annual ivermectin 
at a standard dose of 150 ug/kg. All nodding syndrome participants also received routine care including 
nutritional supplementation and physical therapy as necessary for rehabilitation, and symptomatic treatment 
of seizures with sodium valproate (dose rationalised between 10 – 35 mg/kg/day depending on seizure 
frequency). 
A validated disease staging system was adapted to classify nodding syndrome participants into 3 categories: 
mild, moderate, and severe disease 2,7. Cases were defined to have mild disease if they only had head 
nodding in the absence of convulsive seizures (tonic, clonic, myoclonic, absence, tonic-clonic) or other 
disabilities. Moderately severe disease included children with head nodding and convulsive seizures: tonic, 
clonic, tonic-clonic, myoclonic or absence seizures. Severe disease included cases with convulsive seizures 
and: i) focal neurological deficits (e.g. impaired motor function); ii) recognizable cognitive impairment, 
behavioural disorders or psychiatric disorders; iii) severe malnutrition (severe stunting [height-for-age z 
score < -3] or severe wasting [BMI-for-age z score< -3]); iv) physical deformities including kyphosis, limb, 
and pectus deformities; v) severe disability with limited independent mobility.
Inflammatory marker quantification
Markers of immune and complement activation were measured in plasma and CSF by enzyme-linked 
immunoassays (ELISAs) or custom MagPix Luminex assay. Markers were selected based on previous 
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C-reactive protein (CRP, dilution: 1:20,000 plasma, undiluted CSF), matrix metallopeptidase-9 (MMP-9, 
dilution: 1:2 plasma, undiluted CSF) and chemokine (C-C motif) ligand 5 (CCL5) and regulated on 
activation, normal T cell expressed and secreted [RANTES]; 1:2 plasma, undiluted CSF) using 
commercially available kits (DuoSet® ELISA Development System, R&D Systems, Minneapolis, MN, 
USA). Plasma was tested in duplicate and CSF tested in single replicate due to limited sample volume. 
Assays were performed according to the manufacturer’s instructions except for overnight sample incubation 
at 4°C to increase assay sensitivity. Neopterin assays were performed using a competitive ELISA (DRG 
Instruments, GmbH, Germany) following the manufacturer’s instructions. A custom-developed multiplexed 
fluorescent magnetic bead-based immunoassay (R & D Systems, Minneapolis, USA) was used to measure 
the remaining markers (CXCL10, CXCL13, CXCL9, CCL2, APRIL, BAFF, IL6, IL4, IL13, IL10, TNFα, 
INFγ, C5/C5a) according to the manufacturer’s instructions. Plasma samples were tested using a 2-fold 
dilution, and CSF samples were tested undiluted. 
Statistical Methods
Epi Info™ version 7.1.5, R studio version 3.6.3, and GraphPad Prism version 6.05 for windows were used. 
Proportions were compared using Pearson’s Chi-Square test. For continuous data, the means of normally 
distributed data were compared using the Student’s t-test as appropriate. In case this was not normally 
distributed, data were analysed using the Mann-Whitney U test and presented as medians (interquartile 
range, IQR). The relationship between markers of immune activation in CSF and seizure burden was 
evaluated using a Spearman rank correlation test. The normal range for CSF markers was estimated using 
the 95th centile of control values to establish the upper and lower limits of normal range. A multivariable 
logistic regression analysis was performed to evaluate plasma inflammatory markers associated with 
nodding syndrome adjusting for demographics. As P. falciparum is associated with systemic inflammatory 
responses and there were differences in the prevalence of P. falciparum infections between groups, the 
analysis was stratified by P. falciparum status. Multicollinearity in models was assessed using the variance 
inflation factor (VIF) and confirming that is was < 10. 
Results 
General characteristics 
The mean age of the population was 15.1 (SD 1.9) years and 45.1% were female. The age and sex 
distribution between groups were similar (Table 1). The geographic location of the nodding syndrome cases, 
and community controls is shown in Figure 1. The CSF controls were enrolled from Kampala in central 
Uganda. In children with nodding syndrome, the average time from nodding syndrome diagnosis to 
enrolment in the study was 8.3 (SD 2.7) years, and 62/154 (40.3%) of participants were seizure free in the 
previous 30 days. The major other seizure type reported was mainly generalized tonic-clonic seizures, 
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moderately severe and 89/154 (57.8%) had severe disease. (Table S1). The mean age was 15.5 (SD 1.7), 
and 85/154 (55.2%) of the cases were male. A total of 9/154 (5.8%) nodding syndrome cases were severely 
stunted compared 6/154 (3.9%) community controls p=0.59, while 35/154 (22.7%) cases were severely 
wasted compared to 17/154 (11.0%) community controls p=0.009. 
Although none of the children were acutely ill at the time of enrolment, asymptomatic malaria was common 
occurring in 72.7% (112/154) of participants with nodding syndrome and 54.5% (84/154) of community 
controls with an odds ratio (OR) of 2.2 (95% CI 1.34, 3.68, p=0.001). Among children with nodding 
syndrome there were no differences in the prevalence of malaria among children with mild, moderate or 
severe disease, (p trend = 0.88). One child with nodding syndrome was HIV infected, while none of the 
community children or cancer survivors tested positive for HIV infection. The majority of cases of nodding 
syndrome were seropositive for OV 147/154 (95.4%) compared to community controls 86/154 (55.8%), OR 
17.04 (95% CI 7.33, 45.58, p<0.0001). In addition, the cases had higher relative levels of anti-OV-16 IgG, 
compared to the community controls, the median signal-to-noise (S/N) ratio was 27.0 (IQR, 7.6-46.3) in 
cases compared to 2.40 (IQR, 1.2-10.3) in community controls (p<0.0001) (Figure 2). There was a trend to 
an increased level of anti-OV-16 IgG with disease severity with increasing median [IQR] across mild (12.07 
[3.45-49.31]), moderate (26.6 [9.4-26.6]) and severe (31.4 [9.5-48.9]) signal-to-noise ratio disease although 
this was not significant (p trend=0.06). By skin snip microscopy, active O. volvulus infection was observed 
in 13/154 (8.4%) cases, (the microfilaria [MF] load ranged from 1-88 MF per skin snip), and only 2/154 
(1.3%) among community controls (MF range 1-16 per skin snip). Children with nodding syndrome had 
increased odds of active O. volvulus infection with an OR of 7.0 (95% CI 1.53, 64.70, p=0.006) compared to 
community controls. 
Immune and complement activation in CSF of nodding syndrome   
To investigate pathways of central nervous system inflammation in nodding syndrome, levels of immune 
and complement activation were measured in CSF of children with nodding syndrome and CSF controls 
(Ugandan children in remission for a haematological malignancy). Compared to the normal range 
established in the CSF of CSF controls recovered from haematological malignancy, complement factor 5 
(C5/C5a) was elevated in all cases of nodding syndrome compared to CSF controls (p <0.0001) (Figure 3, 
Table S2). C-reactive protein (CRP), another marker of complement activation was elevated in 56 (36.3%) 
of cases relative to the population normal derived from CSF controls; however, there was no significant 
difference in CRP levels between cases and controls with an OR of 1.44 (95% CI 0.38, 5.32) ( Figure 3, 
Table 2). None of the other markers of immune activation were above or below the normal limits 
determined in greater than 5% of nodding syndrome cases (Table S3), and levels were comparable between 
groups when adjusting for multiple comparisons. Levels of CXCL9, CCL5 (RANTES), IL13, IL6, TNF , 𝛼
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Next, we evaluated whether there were differences in the median levels of CSF markers of immune and 
complement activation in nodding syndrome cases by disease severity (Table 2). No differences in markers 
of immune or complement activation by disease severity were observed according to analysis using a non-
parametric test for trend. Among nodding syndrome cases there was no correlation between markers of 
immune or complement activation and malaria, seizure burden, dose of sodium valproate (mg/kg/day), OV-
16 exposure (S/N) and duration with disease (years). (Figure S1). 
Systemic immune activation in nodding syndrome compared to community controls 
To investigate whether nodding syndrome is associated with systemic changes in inflammatory responses, 
plasma levels of markers of immune or complement activation were measured in nodding syndrome cases 
and compared to healthy community controls. In plasma, using the clinically recognized cut off for elevated 
CRP levels (≥ 10 mg/L), CRP was elevated in 55/154 (33.7%) cases compared to 48/154 (31.1%) controls 
(p= 0.46).  The median CRP levels was 6.45 (2.43-12.19) mg/L in cases compared to 4.34 (1.45-13.35) 
mg/L in the healthy controls, OR of 1.22 (95% CI 0.83, 1.80). Among nodding syndrome cases there was a 
stepwise increase in median CRP levels with disease severity (p trend =0.008). (Table 2). Furthermore, CSF 
and plasma CRP levels were strongly correlated (r=0.7, p>0.0001) (Figure S2). 
Inflammatory markers IL10, APRIL, CCL5 (RANTES), CCL2, CXCL13, MMP-9 were significantly lower 
among cases compared to community controls after adjusting for multiple comparisons. There was no 
significant difference in the level of C5/C5a, IL4, BAFF, or CXCL9 between cases and community controls. 
(Figure 2). In multivariable models, elevated levels of CRP, BAFF and IL4 were independently associated 
with nodding syndrome, while CCL2, IL10, APRIL, and MMP-9 were lower in children with nodding 
syndrome. When stratifying by P. falciparum infection, elevated BAFF and downregulated CCL2 and IL10 
were independently associated with nodding syndrome in children who were malaria-positive and malaria 
negative (Figure 4).  
Among nodding syndrome cases there was no correlation between plasma markers of immune or 
complement activation and seizure burden, dose of sodium valproate (mg/kg/day), OV-16 exposure (S/N), 
duration of illness (years). (Figure S1).  Furthermore, cytokine levels were not significantly affected by O. 
volvulus infection or nutritional status (Table S4, S5). 
 Discussion
This study aimed to examine pathways of immune and complement activation in children with chronic 
nodding syndrome. We observed evidence of complement system activation in the CSF of children with 
nodding syndrome with elevated levels of CRP and C5/C5a. The findings suggest a possible role of central 
nervous system complement activation in the pathogenesis of chronic nodding syndrome. There was 
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immune activation lower in children with nodding syndrome compared to community children. Further 
investigation of the complement system and immune dysregulation is required, particularly in children with 
acute nodding syndrome. 
Inflammation is associated with epileptic and neurological disorders and has been shown to exacerbate 
disease progression25,26.  In the context of nodding syndrome, a recent post-mortem study identified gliosis 
and features of past ventriculitis and/or meningitis in 80% of cases studied suggesting nodding syndrome 
maybe a post-infectious encephalopathy or autoimmune disorder20. Although auto-reactive antibodies have 
been observed in independent case-control studies, no conclusive evidence of neuroinflammation has been 
demonstrated.  In the present study, despite elevated CRP levels in CSF of one-third of cases and a 
significant elevation of complement factor C5/C5a in CSF, there is limited evidence of immune activation in 
both the CSF and peripheral circulation of the cytokines and chemokines tested. Regardless, the observation 
of elevated CRP and of complement activation in CSF are suggestive of ongoing innate immune responses 
within the CSF of children with nodding syndrome. Additional studies to understand pathways of 
complement activation and regulation in samples from children with both acute and chronic nodding 
syndrome, and comparison with CSF from children with other chronic neurodegenerative disorders may 
help elucidate the role of the complement system in nodding syndrome pathogenesis. 
It is unclear why the levels of APRIL, IL10, IL13, CXCL10, CXCL13, and CCL2 were reduced in plasma 
of children with nodding syndrome compared to controls, but similar decreases in levels of Th-2 type 
responses have been observed in individuals with prolonged occult O. volvulus infection27. Furthermore, 
children affected with nodding syndrome are more likely to have a history of chronic malnutrition or other 
infections which may further alter their immune profiles. Interestingly, in all multivariable models nodding 
syndrome was associated with higher plasma levels of BAFF, even after stratifying for malaria infection,  
which is consistent with observations in autoimmune disorders such as systemic lupus erythematosus (SLE) 
28 and Sjögren's syndrome 29. These results support an immunological component to the pathophysiology of 
nodding syndrome. 
The mean duration of nodding syndrome in this study was 8.3 years. During this timeframe children were 
treated using a standard treatment plan aimed at symptomatic care33. This included long-term use of the 
antiepileptic sodium valproate for seizure control 21. Sodium valproate is documented to have anti-
inflammatory properties and may have further modulated immune responses 30–32. These may explain the  
absence of significant immune dysregulation among children receiving treatment 33. Furthermore all 
children in the region received ivermectin biannually, which has been shown to transiently impact cytokine 
levels34. These may have affected the level of immune activation leading to normalization of responses over 
time. Finally, the region is endemic to several infectious diseases which may have confounded inflammatory 
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study did not systematically evaluate other infections, including helminths that have immunomodulatory 
properties38. 
To the best of our knowledge, this is the first study to demonstrate an association between complement 
activation and nodding syndrome. Several cells of the nervous system (astrocytes, neurons, endothelial cells 
and oligodendrocytes) express complement proteins and receptors39. Complement activation has been well 
described in other neurological conditions, including: epilepsy (e.g. post-viral epilepsy, CASPR2-associated 
encephalitis and Rasmussen's syndrome)40,41, major psychiatric disorders (e.g. major depressive disorder and 
schizophrenia)42, and neurological disorders (e.g. Alzheimer’s disease, amyotrophic lateral sclerosis, 
Huntington's disease and parkinsonism)43.  Complement associated proteins have been implicated in several 
neuro-degenerative disorders, and C5/C5a has been associated with neuronal death in vitro 43,44.  In the 
present study, peripheral elevation of complement was not observed suggesting interictal synthesis of C5a 
may occur in nodding syndrome as reported in Guillain-Barré syndrome45. Multiple causes of complement 
dysregulation have been demonstrated including autoantibodies, damaged cells, exposed myelin antigens, 
pathogens, trauma or anoxia39,40,43. The precise mechanism by which this dysregulation may occur or result 
in nodding syndrome disease pathology is unclear. We speculate that complement activation may be 
secondary to an underlying etiological factor resulting in interictal complement synthesis. 
It has been suggested that nodding syndrome may be a post-viral disorder analogous to measles-associated 
SSPE based on clinical and neuropathological overlaps18. Therefore in a similar fashion to viral 
encephalitis46, and septic encephalopathy47, invasion of CSF by a neurotropic viral infection may trigger 
complement activation. In line with this observation, early evidence demonstrated complement activation in 
measles infections48. Nodding syndrome has been liked strongly to O. volvulus however, invasion of CSF by 
O. volvulus has not been demonstrated. Despite this, it is possible that CSF invasion by onchocerca 
metabolites may occur resulting in immune and or complement activation.  O. volvulus has been shown to 
activate the complement cascade however it can also bind human complement factor H which regulates 
complement activation by cleaving C3b into an inactive form averting continued activation27. A breakdown 
in this regulation within the CSF of children with nodding syndrome may have adverse effects.  Finally 
previously identified auto-antibodies13,19 may be neurotoxic through a complement antibody-mediated 
mechanism. 
The study had limitations. Children with nodding syndrome were assessed on average 8 years after their 
initial diagnosis and following treatment. Children had also been on medications for a number of years 
(including bi-annual treatment of O. volvulus infection) that could modulate immune responses and affect 
conclusions drawn. Therefore, prospective enrolment of a cohort of children with new-onset nodding 
syndrome will be important to extend and validate these findings. The CSF controls used in this study were 
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healthy community children, we enrolled controls without evidence of infection or active disease undergoing 
lumbar puncture as part of follow-up care for prior haematological malignancy. These patients may have had 
substantial difference in nutritional status and history of infection compared to children with nodding 
syndrome. While we cannot definitively state that the levels of immune activation in the controls are 
representative of a healthy population, they are consistent with levels reported in the literature23. 
Strengths of this study include the enrolment of a large population of children with nodding syndrome and 
inclusion of controls from the same community. This population is well characterized and data on seizure 
history, disease staging, and medication use were systematically collected which enabled comparisons 
between pathways of interest and disease severity. 
Conclusion
This study demonstrates evidence of complement activation in the cerebrospinal fluid of Ugandan children 
with nodding syndrome. However, in this population with chronic nodding syndrome, receiving 
symptomatic therapy of whom approximately two-fifths had attained good seizure control, there was no 
evidence of systemic immune activation. Future studies are needed to evaluate the spectrum of complement 
proteins and inflammation in incident cases in order to design therapies that can be used in the acute phase 
of disease to mitigate disease progression and improve long-term outcomes in children with nodding 
syndrome. 
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Tables










Age, years, mean (SD) 15.5 (1.7) 14.6 (2.1) 12.3 (1.5) <0.0001*
Male, % (n/N) 55.2% (85/154) 54.5% (84/154) 46.7% (7/15) 0.81**
Height for age z scores, median (IQR) -1.11 (1.81-0.36) -0.8 (-1.62-0.01) NA 0.01#
Severe stunting, % (n/N) (z score<-3) 5.8% (9/154) 3.9% (6/154) NA 0.59**
BMI for age z scores mean (SD) -2.02 (1.47) 1.65 (1.15) NA 0.01##
Severe wasting, % (n/N) (z score<-3) 22.7% (35/154) 11% (17/154) NA 0.009**
MUAC, cm, mean (SD) 22.16 (3.33) 21.76 (2.84) NA 0.26##
Infection
Malaria smear positive, % (n/N) 72.7% (112/154) 54.5% (84/154) 0% (0/15) <0.0001**
HIV infection, % (n/N) 0.6% (1/154) 0% (0/154) 0% (0/154) 0.14**
Seropositive OV16, % (n/N) 95.4% (147/154) 55.2% (86/154) NA <0.0001**
Active O. volvulus infection, % (n/N) 8.4% (13/154) 1.3% (2/154) NA 0.006**
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Table 2: Table comparing markers of immune activation in nodding syndrome case with mild, moderate and severe disease
Plasma CSF












CXCL10, pg/ml 68.32 (50.59, 121.2) 64.85 (44.25, 86.81) 71.47 (43.5, 106.7) 0.84 112.0 (64.4, 172.70) 103.6 (78.96, 214.7) 82.22 (55.06, 143.6) 0.08
CCL2, pg/ml 38.28 (22.01, 63.76) 37.72 (21.24, 80.45) 34.56 (21.24, 63.76) 0.42 256.3 (221.1, 396.1) 244.2 (176.1, 459.4) 237.5 (166.9, 390.7) 0.36
CXCL13, pg/ml 44.73 (24.31, 70.09) 47.31 (25.29, 87.5) 34.8 (25.13, 66.83 0.73 18.96 (15.43, 24.36) 18.96 (15.43, 23.5) 18.96 (14.48, 22.64) 0.50
CXCL9, pg/ml 399.7 (399.7, 878.5) 399.7 (399.7, 923.3) 399.7 (399.7, 619.5) 0.32 ND ND ND -
CCL5(RANTES) ng/ml 2.13 (1.94, 2.59) 2.19 (1.80, 2.62) 2.24 (1.60, 2.82) 0.88 ND ND ND -
IL10, pg/ml 38.18 (29.8, 59.98) 41.25 (33.99, 56.33) 38.18 (20.79, 58.77) 0.14 29.17 (24.59, 33.14) 26.89 (24.05, 38.65) 29.17 (24.39, 38.35) 0.19
IL4, pg/ml 2.42 (2.42, 4.93) 2.42 (2.42, 4.63) 2.42 (2.42, 9.87) 0.21 11.27 (8.02, 13.68) 11.38 (8.54, 13.64) 9.65 (7.23, 12.17) 0.99
IL13, pg/ml 245.2 (245.2, 554.2) 245.2 (245.2, 554.2) 245.2 (245.2, 357) 0.36 ND ND ND -
APRIL, pg/ml 149.7 (97.65, 256.8) 184 (110.7, 267.3) 163.3 (91.48, 230.9) 0.87 45.66 (32.64, 60.87) 41.29 (26.45, 53.42) 36.99 (26.43, 50.08) 0.06
BAFF, pg/ml 664.0 (570.1, 891.9) 643.8 (553.4, 852.9) 647.5 (568.5, 769.5) 0.71 73.65 (58.85, 96.54) 63.41 (49.72, 92.05) 59.58 (47.98, 85.4) 0.07
MMP-9, ng/ml 0.87 (0.65, 1.53) 1.16 (0.74, 1.52) 1.05 (0.71, 1.50) 0.71 ND ND ND -
Neopterin, mmol/L Not measured Not measured Not measured - 2.268 (1.23, 3.90) 2.715 (0.95, 4) 2.84(1.43, 4.0) 0.53
Complement activation
C5/C5a, ng/ml 18.06 (11.54, 29.87) 23.45 (16.69, 31.51) 16.89 (11.33 29.50) 0.47 14.90 (9.53, 21.31) 14.68 (8.73, 18.96) 11.99 (7.79, 19.37) 0.14
CRP, mg/L 4.11 (0.88 – 8.26) 5.58 (2.15, 22.48) 7.71 (4.02, 17.59) 0.008 0.0029 (0.001, 0.003) 0.0024 (0.001, 0.003) 0.00214 (0.0008, 0.003) 0.33
Data presented as median (IQR) and analysed using a non-parametric test for trend.
Abbreviations: CXCL10 – C-X-C motif chemokine 10/ Interferon gamma-induced protein 10, CCL2 – chemokine (C-C motif) ligand 2, CXCL13 – 
chemokine (C-X-C motif) ligand 13, CXCL9 – Chemokine (C-X-C motif) ligand 9, CCL5(RANTES) – Chemokine (C-C motif) Ligand 5 (regulated on 
activation, normal T cell expressed and secreted), IL10 – Interleukin 10, IL4 – Interleukin 4, IL13 – Interleukin 13, April – A proliferation-inducing ligand, 
BAFF – B lymphocyte stimulator, MMP-9 – Matrix metallopeptidase 9, CRP – C -reactive protein, C5/C5a – Complement component, CSF – Cerebral spinal 
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Figure Legends
Figure 1: Study area in northern Uganda
Figure 2: Plasma markers of immune activation in nodding syndrome and community 
controls. Box plots showing plasma levels of markers of immune activation in cases with 
nodding syndrome (Nodding syndrome, n=154, red) and healthy community controls (HC, 
n=154, blue). Box plots represent median and IQR with whiskers denoting the 5% and 95% 
percentiles data compared using Mann-Whitney U test where *p ≤ 0.01, **p ≤ 0.001, ***p ≤ 
0.0001, ****p ≤ 0.00001.  After adjusting for multiple comparisons, IL10, April, RANTES, 
CCL2, CXCL13, MMP-9 and OV-16 remained significant  
Figure 3: Cerebral spinal fluid inflammatory markers in patients with nodding 
syndrome; Box plots showing CSF levels of markers of immune activation in cases of 
nodding syndrome (NS, n=154, red) compared to CSF controls (CC, n=15, blue). Box plots 
represent median and IQR with whiskers denoting the 5% and 95% percentiles data 
compared using Mann-Whitney U test where *p ≤ 0.01, **p ≤ 0.001, ***p ≤ 0.0001, ****p ≤ 











This article is protected by copyright. All rights reserved
Figure 4: Forest plot depicting the relationship between plasma markers of 
inflammation in children with nodding syndrome and community children. Forest plots 
show odds ratio (95% CI) from a multivariable logistic regression model based on a one-unit 
change in log 10 transformed plasma biomarker with nodding syndrome cases as the 
dependent variable. (A) Model with all participants (NS =154 and CC = 154). (B) Model in 
P. falciparum positive individuals (NS=112, CC=84). (C) Model in P. falciparum negative 
participants (NS=42, CC= 70). Adjusted models included participant age, sex, BMI-for–age z 
score, O. volvulus seropositivity, and P. falciparum status (in combined model). Plasma 
markers upregulated in nodding syndrome are shown in red, markers with no change are 
shown in grey and markers down regulated are depicted in blue. Markers significant 
following adjustment for multiple comparisons are indicated with an asterisk.  Markers are 
ordered by odds ratio from highest to lowest within each plot.   
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